A multicentre, multinational prospective observational imaging biomarker study in early stage Huntington’s disease (HD) patients to assess imaging techniques and parameters able to support efficacy studies with SEN0014196 in HD patients during Phase II and III studies
SEN0014196 · Siena Biotech (Italy)
Phase 1/2 study testing an investigational treatment in Huntington's disease.
Recruitment endedPhase 1 / Phase 2Not specifiedISRCTNTreatment trial
Recruiting in: United KingdomExact site not listed by the study registry.
Preparing a short plain-English summary.
